Pharmaseek LLC

1. Moderna TX, Inc. $9,291,650 379 payments
2. AstraZeneca UK Limited $7,905,239 19 payments
3. AstraZeneca Pharmaceuticals LP $6,244,538 28 payments
4. Indivior Inc. $5,374,404 328 payments
5. GlaxoSmithKline, LLC. $4,361,919 781 payments
6. Seqirus USA Inc $4,104,178 1,302 payments
7. Pfizer Inc. $1,852,816 312 payments
8. Sanofi Pasteur Inc. $1,467,158 129 payments
9. AbbVie, Inc. $1,211,498 478 payments
10. Bavarian Nordic A/S $1,207,060 112 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $11,923,164 22 payments
2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $5,852,744 85 payments
3. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $5,088,734 304 payments
4. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $4,104,178 1,302 payments
5. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $2,077,945 5 payments
6. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $1,101,198 208 payments
7. A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi $1,075,841 62 payments
8. A Phase 1/2, First-Time-In Human (Ftih), Randomized, Observer-Blind, P $1,003,838 35 payments
9. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $984,197 65 payments
10. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $837,355 52 payments

1. Patient care $154,539 17 payments
2. Other $133,559 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.